BackNKGen Biotech Overview

NKGen Biotech Other Current Liabilities

Latest other current liabilities for NKGN: $39M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$39.48M
↑ 205.34% YoYΔ $26.55M vs prior year quarter

Peer trimmed avg / median

Loading

NKGen Biotech Other Current Liabilities History

Loading

NKGen Biotech vs. peers: Other Current Liabilities Comparison

Loading

NKGen Biotech Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

NKGen Biotech (NKGN) FAQ

As of the most recent data (March 2025), NKGN shows a other current liabilities of $39M. That compares with $13M in the prior-year period — up 205.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NKGN's other current liabilities is now $39M (was $13M) — a 205.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether NKGen Biotech is outperforming or lagging.

Tracking NKGN's other current liabilities over time shows whether NKGen Biotech is scaling, shrinking, or reshaping that part of the business. The current reading is $39M That compares with $13M in the prior-year period — up 205.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has NKGen Biotech's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $39M) with ownership activity and broader fundamentals.